Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

The ability to respond to changing surroundings was once considered exclusive to complex living organisms. Then came computers, specially designed for stimulus–response tasks, which can take in ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

A new physics study challenges the simulation hypothesis, arguing that the universe contains realities that can likely never ...

Previous Community Perspectives have described threats posed by Artificial Intelligence (AI) and its convergence with the rapidly expanding technological ecosystem — especially nanotechnology, ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in ...

Abstract: Aiming at the shortcomings of traditional convolutional neural network methods in capturing long-range spatial dependencies in fine-grained image recognition due to the restricted sensory ...

Abstract: In industrial measurements, when signal reception is affected by hardware defects or asymmetric interference, I/Q imbalance can occur, which may result in the noise exhibiting noncircular ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals, Inc. before investing. In this article, we go over a ...